Your browser doesn't support javascript.
loading
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad, Nilofer S; Posadas, Edwin M; Kwitkowski, Virginia E; Steinberg, Seth M; Jain, Lokesh; Annunziata, Christina M; Minasian, Lori; Sarosy, Gisele; Kotz, Herbert L; Premkumar, Ahalya; Cao, Liang; McNally, Deborah; Chow, Catherine; Chen, Helen X; Wright, John J; Figg, William D; Kohn, Elise C.
Afiliação
  • Azad NS; Medical Oncology Branch, Biostatistics and Data Management Section, and Genetics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
J Clin Oncol ; 26(22): 3709-14, 2008 Aug 01.
Article em En | MEDLINE | ID: mdl-18669456

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2008 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2008 Tipo de documento: Article